Recent studies have demonstrated that serglycin is overexpressed in a variety of cancers, including colon, breast [7], and lung [8] cancers, and that serglycin overexpression was correlated with a more aggressive malignant phenotype. The gene discussed is SRGN; the disease is cancer.